menu
    • menu
    [{"orgOrder":0,"company":"Hanmi Pharmaceutical","sponsor":"Spectrum Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"SOUTH KOREA","productType":"Protein","year":"2021","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"GCSF","graph1":"Hematology","graph2":"Phase III","graph3":"Hanmi Pharmaceutical","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Hanmi Pharmaceutical \/ Spectrum Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"Hanmi Pharmaceutical \/ Spectrum Pharmaceuticals"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Jefferies","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Public Offering","leadProduct":"Eflapegrastim","moa":"||GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Jefferies","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Jefferies"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2023","type":"Acquisition","leadProduct":"Eflapegrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Assertio Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Assertio Therapeutics","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2023","type":"Acquisition","leadProduct":"Eflapegrastim","moa":"GCSF","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Assertio Therapeutics","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Assertio Therapeutics"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2023","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2022","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"GCSF","graph1":"Hematology","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Hematology","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"||GCSF","graph1":"Hematology","graph2":"Phase I","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Hematology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Spectrum Pharmaceuticals","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"U.S.A","productType":"Protein","year":"2020","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"||GCSF","graph1":"Infections and Infectious Diseases","graph2":"Approved FDF","graph3":"Spectrum Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Spectrum Pharmaceuticals \/ Inapplicable","highestDevelopmentStatusID":"15","companyTruncated":"Spectrum Pharmaceuticals \/ Inapplicable"},{"orgOrder":0,"company":"Assertio Therapeutics","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Protein","year":"2024","type":"Inapplicable","leadProduct":"Eflapegrastim","moa":"||GCSF","graph1":"Oncology","graph2":"Phase I","graph3":"Assertio Therapeutics","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Subcutaneous Injection","sponsorNew":"Assertio Therapeutics \/ Inapplicable","highestDevelopmentStatusID":"6","companyTruncated":"Assertio Therapeutics \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Eflapegrastim

    Menu

    Eflapegrastim

    DEVELOPMENTS

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
    filter

    Year

    filter

    DEALS // DEV.

    filter

    Country

    filter
    Sponsor
    filter

    Therapeutic Area

    filter

    Study Phase

    filter

    Deal Type

    filter

    Product Type

    filter

    Dosage Form

    filter

    Lead Product

    filter

    Target

    refresh Filters
    refresh Reset Filter
    refresh Reset Filter
    price-trend All Developments

    Therapeutic Area by Lead Product

    ForexGraph

    Study Phase by Lead Product

    ForexGraph

    Company by Lead Product

    ForexGraph

    Top Deals by Deal Size (USD bn)

    ForexGraph

    01

    Assertio Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Assertio Therapeutics

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Eflapegrastim,Cyclophosphamide

    Therapeutic Area : Oncology

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Assertio Announces Results of Rolvedon® Same-Day Dosing Clinical Study

    Details : Rolvedon (eflapegrastim) is a leukocyte growth factor SC injection being investigated in patients with early stage breast cancer with docetaxel and cyclophosphamide.

    Product Name : Rolvedon

    Product Type : Protein

    Upfront Cash : Inapplicable

    December 13, 2024

    Lead Product(s) : Eflapegrastim,Cyclophosphamide

    Therapeutic Area : Oncology

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    02

    Spectrum Pharmaceuticals

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Spectrum Pharmaceuticals

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Eflapegrastim

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Approved FDF

    Sponsor : Assertio Therapeutics

    Deal Size : Undisclosed

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Assertio Holdings, Inc. Closes Spectrum Pharmaceuticals Transaction

    Details : Through the acquisition, Assertio will expand its product portfolio by including Rolvedon (eflapegrastim-xnst), a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation for the treatment of febrile neutropenia.

    Product Name : Rolvedon

    Product Type : Protein

    Upfront Cash : Undisclosed

    July 31, 2023

    Lead Product(s) : Eflapegrastim

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Approved FDF

    Sponsor : Assertio Therapeutics

    Deal Size : Undisclosed

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    03

    Spectrum Pharmaceuticals

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Spectrum Pharmaceuticals

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Eflapegrastim

    Therapeutic Area : Hematology

    Study Phase : Approved FDF

    Sponsor : Assertio Therapeutics

    Deal Size : $757.0 million

    Deal Type : Acquisition

    DEALS_DEV arrow-down

    Assertio Holdings, Inc. to Acquire Spectrum Pharmaceuticals, Inc. in All Stock and CVR Transaction

    Details : Through the acquisition, Assertio will expand its product portfolio by including Rolvedon (eflapegrastim-xnst), a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation for the treatment of febrile neutropenia.

    Product Name : Rolvedon

    Product Type : Protein

    Upfront Cash : $291.0 million

    April 25, 2023

    Lead Product(s) : Eflapegrastim

    Therapeutic Area : Hematology

    Highest Development Status : Approved FDF

    Sponsor : Assertio Therapeutics

    Deal Size : $757.0 million

    Deal Type : Acquisition

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    04

    Spectrum Pharmaceuticals

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Spectrum Pharmaceuticals

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Eflapegrastim

    Therapeutic Area : Hematology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Spectrum Pharmaceuticals Provides Update on Rolvedon™ (eflapegrastim-xnst) Injection and Announces Unaudited...

    Details : ROLVEDON™ (eflapegrastim-xnst) injection is a long-acting G-CSF which decreases the incidence of infection, as manifested by febrile neutropenia, in adult patients with non-myeloid malignancies receiving myelosuppressive anti-cancer drugs.

    Product Name : Rolvedon

    Product Type : Protein

    Upfront Cash : Inapplicable

    January 31, 2023

    Lead Product(s) : Eflapegrastim

    Therapeutic Area : Hematology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    05

    Spectrum Pharmaceuticals

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Spectrum Pharmaceuticals

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Eflapegrastim

    Therapeutic Area : Hematology

    Study Phase : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Spectrum Pharmaceuticals Receives FDA Approval for ROLVEDON™ (eflapegrastim-xnst) Injection

    Details : ROLVEDON™ (eflapegrastim-xnst) injection is a long-acting granulocyte colony-stimulating factor (G-CSF) with a novel formulation,is indicated to decrease the incidence of infection, as manifested by febrile neutropenia.

    Product Name : Rolvedon

    Product Type : Protein

    Upfront Cash : Inapplicable

    September 09, 2022

    Lead Product(s) : Eflapegrastim

    Therapeutic Area : Hematology

    Highest Development Status : Approved FDF

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    06

    Hanmi Pharmaceutical

    South Korea arrow
    Peptide Therapy Summit
    Not Confirmed

    Hanmi Pharmaceutical

    South Korea arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Eflapegrastim

    Therapeutic Area : Hematology

    Study Phase : Phase III

    Sponsor : Spectrum Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Hanmi Pharmaceutical Expects U.S. FDA Approval for 2 New Drugs

    Details : Rolontis," a treatment for neutropenia and "Oraxol," as a treatment for metastatic breast cancer are under priority review by FDA. Hanmi is about to announce the results of their BLA/NDA approval respectively.

    Product Name : Rolontis

    Product Type : Protein

    Upfront Cash : Inapplicable

    January 19, 2021

    Lead Product(s) : Eflapegrastim

    Therapeutic Area : Hematology

    Highest Development Status : Phase III

    Sponsor : Spectrum Pharmaceuticals

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    07

    Spectrum Pharmaceuticals

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Spectrum Pharmaceuticals

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Eflapegrastim,Cyclophosphamide

    Therapeutic Area : Hematology

    Study Phase : Phase III

    Sponsor : Jefferies

    Deal Size : Undisclosed

    Deal Type : Public Offering

    DEALS_DEV arrow-down

    Spectrum Pharmaceuticals Announces Proposed Public Offering of Common Stock

    Details : Spectrum expects to use the net proceeds for general corporate purposes, including the continued development of its pipeline assets, sales and marketing activities, pre-launch activities associated with ROLONTIS and potential business development initiat...

    Product Name : Rolvedon

    Product Type : Protein

    Upfront Cash : Undisclosed

    July 29, 2020

    Lead Product(s) : Eflapegrastim,Cyclophosphamide

    Therapeutic Area : Hematology

    Highest Development Status : Phase III

    Sponsor : Jefferies

    Deal Size : Undisclosed

    Deal Type : Public Offering

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    08

    Spectrum Pharmaceuticals

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Spectrum Pharmaceuticals

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Eflapegrastim,Cyclophosphamide

    Therapeutic Area : Infections and Infectious Diseases

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Spectrum Pharmaceuticals Presents Same Day Dosing Data for ROLONTIS® (eflapegrastim) at AACR Virtual Annual M...

    Details : These data in rats suggest that eflapegrastim administered at the time of chemotherapy, rather than waiting 24 hours, may be able to provide prophylaxis against chemotherapy induced neutropenia.

    Product Name : Rolvedon

    Product Type : Protein

    Upfront Cash : Inapplicable

    June 22, 2020

    Lead Product(s) : Eflapegrastim,Cyclophosphamide

    Therapeutic Area : Infections and Infectious Diseases

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth

    09

    Spectrum Pharmaceuticals

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed

    Spectrum Pharmaceuticals

    U.S.A arrow
    Peptide Therapy Summit
    Not Confirmed
    • fda
    • EDQM
    • WHO-GMP
    Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

    Lead Product(s) : Eflapegrastim,Cyclophosphamide

    Therapeutic Area : Hematology

    Study Phase : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    DEALS_DEV arrow-down

    Spectrum Pharmaceuticals Initiates Same Day Dosing Clinical Trial for ROLONTIS® (eflapegrastim)

    Details : The trial will evaluate the duration of severe neutropenia when administered at three different time points on the same day following standard chemotherapy in patients with early stage breast cancer.

    Product Name : Rolvedon

    Product Type : Protein

    Upfront Cash : Inapplicable

    April 30, 2020

    Lead Product(s) : Eflapegrastim,Cyclophosphamide

    Therapeutic Area : Hematology

    Highest Development Status : Phase I

    Sponsor : Inapplicable

    Deal Size : Inapplicable

    Deal Type : Inapplicable

    blank

    Stock Recap
    #PipelineProspector

    Data Compilation
    #PharmaFlow

    Virtual Booth